Middle East And Africa Biopharmaceutical Logistics Market Size & Outlook, 2025-2033
Middle East And Africa Biopharmaceutical Logistics Market Insights
- As highlighted in Reed Intelligence analysis, the Middle East And Africa Biopharmaceutical Logistics Market, valued at USD 11598.39 Million in 2024, is estimated to achieve USD 20885.25 Million by 2033.
- The market is estimated to grow at a CAGR of 6.78% spanning 2025 to 2033.
- By market size, Cold Chain led the By Supply Chain category in 2024.
- The By Supply Chain segment led by Non-Cold Chain is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
![Middle East And Africa Biopharmaceutical Logistics Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/biopharmaceutical-logistics-market-middle-east-and-africa--38725.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- The global Biopharmaceutical Logistics Market size saw Middle East And Africa holding a share of 8.1% in 2024.
- United States is forecasted to account for the leading share of the global market by 2033.
- In Middle East and Africa, Saudi Arabia is forecasted to be the fastest-expanding market, projected to reach USD 6212.61 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 11598.39 Million |
| Market Size In 2033 | USD 20885.25 Million |
| Largest segment | Cold Chain |
| Units | Revenue in USD Million |
| CAGR | 6.78% (2025-2033) |
| Segmnetation Covered | |
| Middle East and Africa |
|
| By Supply Chain |
|
| By Services |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Middle East And Africa Biopharmaceutical Logistics Market Country 2025-2033 (USD Million)
| Middle East and Africa | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Arab Emirates | XX.x | XX.x | XX.x | 4711.27 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Saudi Arabia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| South Africa | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Egypt | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nigeria | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Turkey | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Middle East And Africa Biopharmaceutical Logistics Market By Supply Chain 2025-2033 (USD Million)
| By Supply Chain | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cold Chain | XX.x | XX.x | XX.x | 6688.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-Cold Chain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Middle East And Africa Biopharmaceutical Logistics Market By Services 2025-2033 (USD Million)
| By Services | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mode of Transportation | XX.x | XX.x | XX.x | 6031.16 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Warehousing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
